Company: Clovis Oncology ($CLVS)
Based: Boulder, CO
Raised: $130 million (10M shares of stock at $13)
Target range: $13 to $15
Current price: $14.54

Scoop: Clovis Oncology CEO Patrick Mahaffy, a Pharmion co-founder, raised $145 million in venture capital with no drugs in the pipeline, but a slate of experienced biotech executives dedicated to identifying a handful of promising oncology drug programs for development. The company, which was named a 2009 Fierce 15 winner the same year it was founded, quickly got to work inking a string of deals with promising developers in the field. First came a $380 million deal with Clavis Pharma for midstage pancreatic drug CP-4126. Pacts with Avila Therapeutics ($209M), another deal with Clavis, and a companion diagnostics deal with Swiss drug giant Roche soon followed. 

In November, Clovis decided it was time to take its chances on the public market, aiming for the sale of 10 million shares for $13 to $15 each. The developer ultimately priced at the low end of its range, which is still an accomplishment in a year in which so many biotechs had to cut their prices in order to go public. Clovis plans to use the funding to support its pipeline of ambitious drug programs.